O-013

Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies

Authors

Zucchelli G 1
Marmorino F 1
Rossini D 1
Aprile G 2
Casagrande M 3
Lonardi S 4
Murgioni S 5
Dell’Aquila E 6
Tomasello G 7
Moretto R 1
Antoniotti C 8
Borelli B 1
Urbano F 9
Ronzoni M 10
Zaniboni A 11
Manglaviti S 12
Buonadonna A 13
Ritorto G 14
Masi G 1
Allegrini G 15
Falcone A 1
Cremolini C 1
Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy Department of Oncology, San Bortolo General Hospital, Vicenza (VI), IT, Vicenza, Italy Department of Oncology, University Hospital, Udine, Italy, Udine, Italy Veneto Oncology Institute, Padua, Italy Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy Department of Medical Oncology, Campus Bio-Medico - University of Rome, Rome, Italy Oncology Unit, Oncology Department, ASST of Cremona, Cremona, Italy Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy Department of Radiological Science, Oncology and Patology, Policlinico Umberto I, Rome, Italy Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy Medical Oncology Unit, Poliambulanza Foundation, Brescia, Italy Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Dipartimento di Oncologia Clinica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy, Aviano, Italy SSD ColoRectal Cancer Unit Dipartimento Oncologia AOU Città della Salute e della Scienza di Torino, Torino, Italy Unit of Medical Oncology, Livorno Hospital, Azienda Toscana Nord Ovest, Livorno, Italy

Stay in the know.
OncNet Newsletter